Cytek Biosciences (NASDAQ:CTKB) Issues Quarterly Earnings Results, Misses Expectations By $0.36 EPS

Cytek Biosciences (NASDAQ:CTKB) posted its quarterly earnings data on Thursday. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.36), FiscalAI reports. Cytek Biosciences had a negative net margin of 33.02% and a negative return on equity of 7.51%. The business had revenue of $62.14 million during the quarter, compared to analysts’ expectations of $58.80 million.

Here are the key takeaways from Cytek Biosciences’ conference call:

• Q4 revenue reached $62.1 million (+8% YoY) — the company’s highest quarterly revenue ever — and full-year 2025 revenue was $201.5 million (+1% YoY) after acceleration in the second half of the year.
• Recurring revenue strengthened meaningfully, representing 34% of total revenue and growing 21% YoY, while Cytek Cloud users exceeded 24,000 (over 50% growth), supporting product stickiness and reagent uptake.
• Product traction broadened: installed base rose to 3,664 units (+208 in Q4), the Aurora Evo and Muse Micro showed strong early adoption, and reagent revenue grew >20% in Q4 (>25% for the year).
• Profitability was pressured as GAAP gross margin fell to 52% and operating expenses increased (notably higher G&A from legal/patent costs), resulting in a 2025 GAAP net loss of $66.5 million that included a large, non‑cash deferred tax valuation allowance.
• Management guided 2026 revenue of $205M–$212M (≈2%–5% growth), expects continued positive adjusted EBITDA, and highlighted operational moves (new Singapore manufacturing site went live quickly) to support growth and supply resilience.

Cytek Biosciences Stock Performance

NASDAQ:CTKB traded up $0.08 during trading hours on Friday, hitting $4.48. The company’s stock had a trading volume of 1,398,770 shares, compared to its average volume of 802,511. The company has a market capitalization of $572.81 million, a PE ratio of -8.78 and a beta of 1.30. Cytek Biosciences has a 52-week low of $2.37 and a 52-week high of $6.18. The business’s 50-day moving average is $4.95 and its two-hundred day moving average is $4.56.

Institutional Trading of Cytek Biosciences

Large investors have recently bought and sold shares of the company. Federated Hermes Inc. grew its position in shares of Cytek Biosciences by 150.9% in the second quarter. Federated Hermes Inc. now owns 7,221 shares of the company’s stock valued at $25,000 after purchasing an additional 4,343 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new stake in Cytek Biosciences in the 3rd quarter valued at approximately $43,000. Captrust Financial Advisors acquired a new stake in Cytek Biosciences during the 2nd quarter valued at $43,000. Maryland State Retirement & Pension System purchased a new position in Cytek Biosciences during the fourth quarter worth $79,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Cytek Biosciences by 338.1% in the second quarter. Tower Research Capital LLC TRC now owns 19,760 shares of the company’s stock worth $67,000 after acquiring an additional 15,250 shares during the last quarter. Institutional investors and hedge funds own 69.46% of the company’s stock.

Cytek Biosciences News Summary

Here are the key news stories impacting Cytek Biosciences this week:

• Positive Sentiment: Revenue beat and record top-line: Cytek reported Q4 revenue of $62.14M, above consensus (~$58.8M) and commentary described record revenue despite challenges — a sign demand for its flow‑cytometry products remains intact. Article Title
• Positive Sentiment: FY2026 revenue guidance in a wide range ($205M–$212M) is broadly in line with street estimates (consensus ~$207.4M), giving some direction on growth expectations for the year. Article Title
• Neutral Sentiment: Earnings materials and transcript released — these provide management color on margin dynamics, headcount/cost actions and product rollout timelines that investors will parse for recovery signs. Earnings Presentation
• Neutral Sentiment: Full earnings call transcript is available for detail on items affecting profitability (one‑time charges, FX, inventory). Investors will judge whether margin headwinds are transitory. Call Transcript
• Negative Sentiment: Large EPS miss and continued unprofitability: CTKB reported a loss per share (reported –$0.34) well below the ~$0.02 consensus, and the company shows a negative net margin (~‑6.5%) and negative ROE — key reasons for downward pressure on the stock. Earnings Summary
• Negative Sentiment: Conflicting EPS/earnings summaries from outlets (some note a small loss vs street) add uncertainty and may amplify short‑term volatility as analysts update models. Zacks Article
• Neutral Sentiment: Short interest data in the feed appears unreliable/zeroed out (NaN/0) and likely isn’t a meaningful driver today. Short Interest Note

Wall Street Analysts Forecast Growth

CTKB has been the subject of a number of recent research reports. TD Cowen restated a “buy” rating on shares of Cytek Biosciences in a research note on Thursday, January 8th. Zacks Research downgraded Cytek Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Cytek Biosciences in a research note on Monday, December 29th. Morgan Stanley began coverage on Cytek Biosciences in a report on Monday, December 1st. They issued an “equal weight” rating and a $6.00 price target for the company. Finally, Piper Sandler cut their price objective on shares of Cytek Biosciences from $8.00 to $7.50 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cytek Biosciences currently has an average rating of “Hold” and a consensus target price of $5.50.

Cytek Biosciences Company Profile

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.